TI
AUTL

Trexquant Investment’s Autolus Therapeutics AUTL Stock Holding History

Trexquant Investment’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,956
Closed -$93K – 1343
2021
Q4 		$93K Buy
+17,956
New +$108K 0.01% 1239
2021
Q3 		– Sell
-41,372
Closed -$275K – 1124
2021
Q2 		$275K Buy
+41,372
New +$257K 0.02% 753
2020
Q4 		– Sell
-18,646
Closed -$217K – 1015
2020
Q3 		$217K Sell
18,646
-25,547
-58% -$370K 0.01% 1047
2020
Q2 		$708K Buy
+44,193
New +$490K 0.05% 532

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Trexquant Investment's AUTL Position: Q1 2022 in Review

Trexquant Investment sold out of Autolus Therapeutics (AUTL) in Q1 2022, closing a stake of 17,956 shares — an estimated $93K sold.

Trexquant Investment first reported a position in AUTL in Q2 2020 and held it in 4 quarters. The position peaked at $708K in Q2 2020. 66 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

  • Trexquant Investment reported no remaining Autolus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Trexquant Investment sold 17,956 Autolus Therapeutics shares in Q1 2022, an estimated $93K.
  • Trexquant Investment first reported a position in Autolus Therapeutics in Q2 2020 and held it in 4 quarters.
  • Trexquant Investment's Autolus Therapeutics position peaked at $708K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.